Glioblastoma multiforme and hepatitis B: Do the right thing (s)

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 23, 2014, Pages 3629-3631

  Purchiaroni, F ^a   Begini, P ^a   Minniti, G ^a   Gallina, S ^a   Delle Fave, G ^a   Marignani, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Chemotherapy; Glioblastoma multiforme; Hepatitis B reactivation; Oncology; Temozolomide

Indexed keywords

DEXAMETHASONE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; TEMOZOLOMIDE;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADULT; ARTICLE; BRAIN EDEMA; CANCER RADIOTHERAPY; CASE REPORT; DRUG DOSE INCREASE; ECHOGRAPHY; GLIOBLASTOMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MIDDLE AGED; PROPHYLAXIS; RELAPSE; SEROLOGY; VIRUS REACTIVATION;

EID: 84942274697     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
2. YEO W, CHAN PK, HO WM, ZEE B, LAM KC, LEI KI, CHAN AT, MOK TS, LEE JJ, LEUNG TW, ZHONG S, JOHNSON PJ. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934.
3. FUJIMOTO Y, HASHIMOTO N, KINOSHITA M, MIYAZAKI Y, TANAKA S, YAKUSHIJIN T, TAKEHARA T, KAGAWA N, YOSHIMINE T. Hepatitis B virus reactivation associated with temozolomide for malignant glioma: a case report and recommendation for prophylaxis. Int J Clin Oncol 2012; 17: 290-293.
4. STUPP R, MASON WP, VAN DEN BENT MJ, WELLER M, FISHER B, TAPHOORN MJ, BELANGER K, BRANDES AA, MAROSI C, BOGDAHN U, CURSCHMANN J, JANZER RC, LUDWIN SK, GORLIA T, ALLGEIER A, LACOMBE D, CAIRNCROSS JG, EISENHAUER E, MIRIMANOFF RO; EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER BRAIN TUMOR AND RADIOTHERAPY GROUPS; NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
5. LOUIS DN, OHGAKI H, WIESTLER OD, CAVENEE WK, BURGER PC, JOUVET A, SCHEITHAUER BW, KLEIHUES P. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
6. KOHRT HE, OUYANG DL, KEEFFE EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006; 24: 1003-1016.
7. TUR-KASPA R, LAUB O. Corticosteroids stimulate hepatitis B virus DNA, mRNA and protein production in a stable expression system. J Hepatol 1990; 11: 34-36.
8. SCARINGI C, DE SANCTIS V, MINNITI G, ENRICI RM. Temozolomide-related hematologic toxicity. Onkologie 2013; 36: 444-449.
9. STUPP R, DIETRICH PY, OSTERMANN KRALJEVIC S, PICA A, MAILLARD I, MAEDER P, MEULI R, JANZER R, PIZZOLATO G, MIRALBELL R, PORCHET F, REGLI L, DE TRIBOLET N, MIRIMANOFF RO, LEYVRAZ S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
10. FIRPI RJ, NELSON DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008; 22: 117-126.
11. MARIGNANI M, GIGANTE E, BEGINI P, MARZANO A, DI FONZO M, DELI I, GALLINA S, COX MC, DELLE FAVE G. Patients with hematological malignancies and serological signs of prior resolved hepatitis B. World J Gastrointest Oncol 2012; 4: 37-45.
12. MARZANO A, ANGELUCCI E, ANDREONE P, BRUNETTO M, BRUNO R, BURRA P, CARACENI P, DANIELE B, DI MARCO V, FABRIZI F, FAGIUOLI S, GROSSI P, LAMPERTICO P, MELICONI R, MANGIA A, PUOTI M, RAIMONDO G, SMEDILE A; ITALIAN ASSOCIATION FOR THE STUDY OF THE LIVER. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007; 39: 397-408.
13. LUBEL JS, TESTRO AG, ANGUS PW. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Intern Med J 2007; 37: 705-712.
14. LOK AS, MCMAHON BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
15. ARTZ AS, SOMERFIELD MR, FELD JJ, GIUSTI AF, KRAMER BS, SABICHI AL, ZON RT, WONG SL. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol 2010; 28: 3199-3202.
16. OHNO M, NARITA Y, MIYAKITA Y, UENO H, KAYAMA T, SHIBUI S. Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide-case report. Neurol Med Chir (Tokyo) 2011; 51: 728-731.
17. CHHEDA MG, DRAPPATZ J, GREENBERGER NJ, KESARI S, WEISS SE, GIGAS DC, DOHERTY LM, WEN PY. Hepatitis B reactivation during glioblastoma treatment with temozolomide: a cautionary note. Neurology 2007; 68: 955-956.
18. GREWAL J, DELLINGER CA, YUNG WK. Fatal reactivation of hepatitis B with temozolomide. N Engl J Med 2007; 356: 1591-1592.